Schedule 13D ownership disclosure
EIDOS THERAPEUTICS INC
Security class unavailable · CUSIP: 28249H104
Event date: 2018-06-22
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 54.8000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-18-233959
- Form type
- SC 13D
- Filer
- BridgeBio Pharma, Inc.
- CIK
- CIK 1743881
- Filed
- Aug 01, 2018
- Reporting period
- Jun 22, 2018
- Description
- Schedule 13D beneficial ownership